ATTENTION: Please enable Javascript in your browser for full site functionality.
Skip to navigation Skip to main content Skip to footer

Updates

SUB-TYPE:

Alliance Healthcare Opens Access to Cancer Symptom Referral Scheme to UK Pharmacies Following Successful Launch Across Alphega Pharmacy Network

 

The ‘Not Normal for You?’ (NNFY) scheme, which enables pharmacists to refer patients showing potential cancer symptoms to their GPs, will be available to pharmacies across the UK following Alliance Healthcare’s decision to expand the scheme to all pharmacies.

 

As part of the rollout, Alliance Healthcare will provide pharmacies with marketing materials - including leaflets and referral cards, free-of-charge, as part of their standard delivery.

 

The scheme, pioneered by Alphega Pharmacy member - Jackie Lewis, owner of Lewis Pharmacy in Exmouth, was rolled out across the Alphega Pharmacy network of more than 1,000 pharmacies in the UK in October 2023.

 

Through the scheme, pharmacy teams are trained to spot potential early symptoms of cancers and other illnesses. All pharmacy staff, from counter assistants to pharmacists, will be trained to look for ‘red flag’ symptoms and behaviour, which may be indicative of certain cancers.

 

Following the identification of symptoms, a pharmacist can discuss the issue with the individual and encourage them to visit their GP if appropriate. Symptoms are written on the back of an eye-catching ‘Not Normal for You?’ orange referral card which can be presented to a GP inorder to confirm symptoms. Although the NNFY card does not enable a faster GP visit, it acts as a mode of validation of symptoms which makes it quicker for a GP to give a referral.

 

The brightly coloured referral card often acts as a prompt for patients to book an appointment with their GP, further increasing the likelihood of diagnosis after potential symptoms have been identified by pharmacy staff.

 

card

 

The initial rollout of the scheme across Alphega pharmacies showed that NNFY was extremely effective in enabling pharmacists to refer patients to their GPs, which was largely due to the existing relationship between pharmacy staff and their patients.

 

Jackie Lewis first rolled out the scheme to 10 pharmacies across East Devon after she was awarded £10,000 in funding from the National Pharmacy Association’s (NPA’s) Health Education Forum. Jackie is also extremely grateful to Bristol Myers Squibb for their grant which enabled material development, upscale and roll out of the project. The pilot of the scheme was a success and led to its rollout across Alphega pharmacies.

 

Jackie has also developed a free online training programme called: ‘Let’s communicate cancer’ which aims to teach pharmacy teams about cancer symptoms using videos and quizzes. The resource is hosted on the British Oncology Pharmacy Association website and the NPA’s websites.

 

During the pilot a patient in one pharmacy was encouraged to visit his GP following a repeat request for purchase of cough medicine. The pharmacist concerned attended a practice meeting and was informed that this particular patient had been diagnosed with lung cancer as a result of her referral, six months later his wife came into the pharmacy and thanked the pharmacist as her husband was now in remission.

 

This case study is in Module 1 of Let’s Communicate Cancer.

 

The pilot also revealed several cases of skin cancer.

 

Participation in the scheme will be open to pharmacies across the UK. More information about the scheme and how to participate can be found at: Bopa.org.uk/cancerhub

 

Jackie Lewis  said: “The ‘Not Normal for You?’ scheme offers pharmacists and their staff resources and training for the early identification of cancer in patients visiting their pharmacy. The timely detection of cancer is incredibly important and I would encourage pharmacies across the UK to participate in the scheme. By equipping frontline healthcare providers with the tools to recognise potential symptoms, lives can be saved through early treatment.”

 

Dr Mandeep Mudhar, Head of Alphega Pharmacy UK, adds: “The ‘Not Normal for You?’ scheme has been positively received by Alphega Pharmacy members and engagement continues to increase. With 1.6 million people visiting their community pharmacy each day in England, pharmacists are well-placed to support, and Jackie has worked tirelessly to increase awareness and empower pharmacists to have more agency when supporting their patients. We will continue to encourage our members and pharmacies to offer this service to their patients as part of our ambition to create healthier futures for all.”

SUB-TYPE: CLASS 3 RECALL

Class 3 recall- Co-Codamol 8/500mg effervescent tablets (Key pharmaceuticals livery

Accord-UK Ltd is recalling a specific batch of Co-Codamol 8/500mg Effervescent Tablets (Key Pharmaceuticals Livery) as a precautionary measure due to the internal tablet blister strips being printed with an incorrect expiry date.

 

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-accord-uk-ltd-co-codamol-8-slash-500mg-effervescent-tablets-key-pharmaceuticals-livery-el-24-a-slash-12?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=5bbfbb93-89fc-44d3-8872-098e5dc41b46&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

Alliance do not stock

CO-CODAMOL EFF TAB 8/500MG

Accord (Key livery)

G2301502

 

 

Further Information

 

For medical information enquiries please contact Accord-UK Ltd’s Medical Information Department on 01271 385257, or email medinfo@accord-healthcare.com

For stock control enquiries please contact Accord-UK Ltd’s Customer Services Team on 0800 373573, or email customerservices@accord-healthcare.com

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE:

Early May 2024 bank holiday opening hours

 

To help keep our customers informed of changes to our service, we have published our Early May 2024 bank holiday opening hours for pharmacy and retail customers.

 

Early May 2024 bank holiday opening hours - England, Scotland, Wales and Northern Ireland

 

Early May 2024 bank holiday opening hours - Channel Islands and Isle of Man

SUB-TYPE: CLASS 3 RECALL

Class 3 recall- OPDIVO 10 mg/mL concentrate for solution

Bristol-Myers Squibb Pharmaceuticals Limited has informed the MHRA that a potential product quality issue has been detected, relating to incomplete crimping of the metal crimp cap of OPDIVO 10mg/mL concentrate for solution for infusion (nivolumab) (1VLX10ML)

 

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-bristol-myers-squibb-pharmaceuticals-limited-opdivo-10-mg-slash-ml-concentrate-for-solution-for-infusion-nivolumab-el-24-a-slash-11

 

Pip code

Product Description

Affected Batches

Alliance do not stock

OPDIVO 10 mg/mL concentrate for solution

8053520

 

 

Further information

For medical information enquiries please contact the Bristol Myers Squibb Medical Information Department by phone (0800 731 1736) or email medical.information@bms.com.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE:

Best Kept Secret: the value of Clinical Homecare to the NHS, patients and society

 

A new independent report commissioned by the NCHA has been released, shining new light on the value of Clinical Homecare. ‘Best Kept Secret: the value of Clinical Homecare to patients, the NHS and society’ has been steered by an independent panel of experts and shines new light on the benefits of homecare to patients, NHS and society.

 

Clinical Homecare can significantly enhance patients’ lives, enabling them to maintain independence, sustain relationships and pursue work or education. Clinical Homecare also provides significant financial savings and benefits to the NHS and wider society. Despite this, Clinical Homecare remains absent from long-term NHS plans, resulting in a significant missed opportunity.

 

Follow this link to read the full report: clinicalhomecare.org/bestkeptsecret

 

Alcura is proud to be a full member of the NCHA, adhering to its stringent Code of Practice and membership criteria. Our commitment to these standards ensures that we provide patients, healthcare professionals and commissioners with the assurance of rigorous excellence in all aspects of Clinical Homecare services we offer.

 

BKS

SUB-TYPE: CLASS 4 CAUTION IN USE

Class 4 caution in use-Freeflex Sodium chloride 0.9%

Fresenius Kabi Limited has informed the MHRA of an error on the infusion bag packaged into the specific batches of Sodium Chloride Intravenous Infusion 0.9% Freeflex.

 

MHRA drug alert date: 21st March 2024

 

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-fresenius-kabi-limited-sodium-chloride-intravenous-infusion-0-dot-9-percent-freeflex-el-24-a-slash-10

 

Pip code

Product description

Supplier

Batch Numbers

Alliance do not stock

Sodium Chloride Intravenous Infusion 0.9% Freeflex.

Fresenius Kabi

13SMR091
13SMR061
13TAR011
13SLR271

 

 

This is a caution in use only we are not accepting stock returns

 

Further information

For more information or medical information queries please email Medical.Information-UK@fresenius-kabi.com or telephone +44 (0)1928533575

For stock control enquiries please contact FK.complaints-uk@fresenius-kabi.com or telephone +44 (0) 1928 533758

SUB-TYPE: FIELD SAFETY NOTICE

Field safety notice-Carboflex dressings

Field safety notice-Carboflex dressings

We have received a recall from Convatec regarding two sizes of Carboflex dressings

 

Date of recall: 19/03/24

 

PIP CODE

DESCRIPTION

SUPPLIER

AFFECTED BATCH

2527372

CARBOFLEX N/ADH S7661 8X15CM

CONVATEC VIA NWOS

3J02333
3L04810

2527380

CARBOFLEXN/ADH  S7662 15X20CM

CONVATEC LTD (WOUNDCARE)

3J00675
3J02320
3J02332
3L04811
4A00343

 

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

 

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE: CLASS 3 RECALL

Class 3 recall- Oestrogel Pump-Pack 750 micrograms/actuation Gel

Besins Healthcare (UK) Ltd has informed the MHRA that a defective pump system was detected in two batches of Oestrogel Pump-Pack 750 micrograms/actuation Gel.

 

 

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-3-medicines-recall-besins-healthcare-uk-ltd-oestrogel-pump-pack-750-micrograms-slash-actuation-gel-estradiol-el-24-a-slash-09?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2a4a39f7-3462-4017-8038-15c956ac6096&utm_content=immediately

 

Pip code

Product description

Supplier

Batch Numbers

2171775

OESTROGEL CAN

BESINS HEALTHCARE (ALLFS)

74800

74830

 

 

Further Information

 

For medical information enquiries please contact the Besins Healthcare UK Ltd Medical Information via email besins@eu.propharmagroup.com or by calling +44 (0)1748 828 789.

For stock control enquiries please contact Besins Healthcare UK Ltd Supply Chain via email supplychain-bhuk@besins-healthcare.com.

 

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

SUB-TYPE:

Alliance Healthcare UK entered into a new wholesale agreement with Opella Healthcare (T/A Sanofi Consumer Healthcare): February 2024

 

We are pleased to announce that, as of 01 February 2024, Alliance Healthcare UK has become one of the chosen wholesalers to supply Opella Healthcare’s (trading as Sanofi Consumer Healthcare) consumer healthcare products to all pharmacies in the United Kingdom.

 

Opella Healthcare’s consumer healthcare portfolio includes the brands Cialis®Together, Allevia®, Buscopan®Dulcolax® and Phenergan®.

 

Click here for full product details.

SUB-TYPE: CLASS 2 RECALL

class 2 recall-Sodiofolin 50 mg/ml, solution for injection/infusion 8ml

medac GmbH (t/a medac Pharma LLP) is recalling the product for the batch specified in this notification due to particles detected during long-term stability tests.

 

 

MHRA drug alert date:12/03/24

 

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-medac-gmbh-t-slash-a-medac-pharma-llp-sodiofolin-50-mg-slash-ml-solution-for-injection-slash-infusion-folinic-acid-400mg-slash-8ml-vial-el-24-a-slash-08?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=b4b7a401-8a7a-4596-8818-f021b9fcd1d9&utm_content=immediately)

 

Pip code

Product description

Supplier

Batch Numbers

ALLIANCE DO NOT STOCK

Sodiofolin 50 mg/ml, solution for injection/infusion 8ml

medac GmbH

E230320B

 

 

Further Information

For all medical enquiries, please contact medical information at medac Pharma LLP by email to info@medacpharma.co.uk or by telephone 01786 458086